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Peripheral blood mononuclear cellsAberrant DNA methylation can lead to genome destabilization and to deregulated gene expression. Recently, 5-
hydroxymethylcytosine (5hmC), derived from oxidation of 5-methylcytosine (5mC) by the Ten-Eleven Translo-
cation (TET) enzymes, has been detected. 5hmC is now considered as a new epigenetic DNA modiﬁcation with
relevant roles in cell homeostasis regulating DNA demethylation and transcription. Our aim was to investigate
possible changes in the DNA methylation/demethylation machinery in MS. We assessed the expression of en-
zymes involved inDNAmethylation/demethylation in peripheral bloodmononuclear cells (PBMCs) from40 sub-
jects with MS and 40 matched healthy controls. We performed also, DNA methylation analysis of speciﬁc
promoters and analysis of global levels of 5mC and 5hmC. We show that TET2 and DNMT1 expression is signiﬁ-
cantly down-regulated in MS PBMCs and it is associated with aberrant methylation of their promoters. Further-
more, 5hmC is decreased in MS PBMCs, probably as a result of the diminished TET2 level.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Multiple sclerosis (MS) is a chronic inﬂammatory and neurodegener-
ative pathology of the central nervous system (CNS) [1,2]. Recently, a
role of epigenetic alterations in the development of neurodegenerative
diseases, including MS pathology, has been described. Notably, MS indi-
viduals show DNA methylation changes in white brain matter with a
decrease by about 2/3 [3]. The aberrant reprogramming of DNAmethyl-
ation patterns is particularly detrimental as, apart from inducing genome
destabilization, it can deregulate genes that should remain silent in the
brain [4]. An example is represented by the enzyme peptidyl arginine
deiminase 2 (PAD2), whose promoter is demethylated inMSwhitemat-
ter [3]. Demethylation causes PAD2 overexpression with consequentental Neurological Therapies
ce, Mental Health and Sensory
niversity of Rome, Rome, Italy.
Cellular Biotechnologies and
za” University of Rome, Rome,
etti), caiafa@bce.uniroma1.itincrease of citrullines on myelin basic protein (MBP) and, thus, myelin
destabilization [5–7]. We showed that PBMCs of MS patients mirror the
up-regulation of PAD2 which, even in these cells, is demethylation de-
pendent [8]. To further characterize the epigenetic changes occurring
in MS we have now investigated the expression of DNAmethyltransfer-
ase (DNMT1, 3a, 3b) and Ten-Eleven Translocation (TET1, TET2, TET3)
family enzymes involved in the formation of 5-methylcytosine (5mC)
and 5-hydroxymethylcytosine (5hmC), respectively. 5hmC is considered
an epigeneticmarkwith autonomous properties, “the sixth base of DNA”
as conﬁrmed by its involvement in transcriptional regulation. It seems to
act as a repulsive factor of 5mC-binding proteins or as a recruiter of pro-
teins which speciﬁcally bind to it. As concerns genomic distribution in
normal human tissues, 5hmC is generally associated with the body of
transcribed genes and thus it is positively correlated with transcription
levels [9–12].
Considering 5hmC abundance in brain with respect to other tissues
and the DNA demethylation observed in MS white matter [3], we hy-
pothesized that variation in peripheral bloodmay be an indicator of on-
going alterations in the central nervous system. This hypothesis was
supported by data on PAD2 [8] and on higher serum brain-derived neu-
rotrophic factor levels inMS patients vs. healthy controls [15]. Addition-
al evidence was reported for DNA methylation changes in Parkinson
disease [13] and during acute ischemic stroke [14].
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down-regulated in MS peripheral blood mononuclear cells through an
aberrant methylation of their promoter. In harmony with this ﬁnding
we observed a decrease of 5hmC.
2. Methods
2.1. MS patients and healthy donors
We analyzed freshly isolated PBMCs from 40 subjects (not receiving
disease modifying therapies) with deﬁnite MS and 40 healthy volun-
teers matched for gender and age. Of 40 patients, 23 were part of a pre-
vious study [8]. All samples were drawn at least 3 months after the last
immunomodulatory therapy. A contrast-enhanced magnetic resonance
imaging (MRI) was performed in MS patients within 24 h from sam-
pling. Demographic and clinical details of patients and healthy subjects
are summarized in Table 1; serological values were in the normal range.
2.2. Isolation of PBMCs from peripheral blood
PBMCs were obtained by centrifugation of whole blood (∼6 ml)
through “Lymphoprep” solution (Axis-Shield) at 1800 rpm for 20 min
at room temperature; lymphocyte–monocyte fraction was taken,
washed twice with PBS and centrifuged at 1200 rpm for 10 min at
room temperature. About 6 × 106 cells were recovered and subdivided
in vials containing 3 × 106 cells whichwere kept in liquid nitrogen until
further use.
2.3. Quantitative real-time PCR
RNA (from 3x106 cells) was extracted with the RNeasy micro kit
(Qiagen) and treated with RNase-free DNase (Qiagen). The RNA concen-
tration and purity (260/280 and 260/230 wavelength absorbance ratio)
were analyzed using the ND-1000 Spectrophotometer (NanoDrop Tech-
nologies). Total RNAwas subjected to reverse transcription using the Su-
perScript VILO cDNA Synthesis Kit (Life technologies). Quantitative PCR
reactions were performed with EXPRESS qPCR Supermix Universal (Life
Technologies) using iCycler IQ detection system (Bio-Rad). Gene expres-
sion analysis was performed using the comparative cycle threshold
method with GUSB for normalization, the most stable reference gene in
multiple sclerosis [8]. The following TaqMan Gene Expression Assays
IDs were used: Hs00154749_m1 DNMT1, Hs01027166_m1 DNMT3a,
Hs00171876_m1 DNMT3b, Hs00286756_m1 TET1, Hs00758658_m1
TET2, Hs00379125_m1TET3, Hs99999908_m1 GUSB (Life technologies),
and Hs.PT.58.1518186 IL-1β (Integrated DNA technologies).Table 1
RR, Relapsing-remitting; SP, Secondarily Progressive; EDSS, Expanded Disability Status Scale; M





Disease duration (range, years)
EDSS median (range)
Disease-modifying therapies
MRI ﬁndings at time of sampling
B. Previous therapies Interferon β1a Interferon β1b Natalizumab
Number of prescribed therapies 28 9 5
Each patient was subjected to more than one therapy.
C. Demographic and clinical data of healthy subjects
Number
Female/Male
Age (years)2.4. Statistical analysis
The non-parametric Mann–Whitney test was applied to compare
quantitative data obtained from healthy and MS donors; the statisti-
cal analysis was performed using the GraphPad prism software.
Spearman correlation analysis was performed to identify the rela-
tionship between continuous variables. Statistical signiﬁcance was
accepted as p b 0.05.2.5. Western blot analysis
Total cell lysates of PBMCs (20 μg) were prepared in RIPA buffer
(50 mM Tris–HCl at pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS and 1 mM EDTA) and normalized for protein
concentration. RIPA buffer was supplemented with protease inhibitor
cocktail (Complete EDTA-free, Roche Applied Science). Protein extracts
were resolved by SDS-PAGE, transferred onto Hybond-ECL nitrocellu-
lose membranes (Amersham Biosciences) and probed with the follow-
ing antibodies: anti-DNMT1 monoclonal antibody (Imgenex) and anti-
TET2 polyclonal antibody (Santa Cruz).2.6. EpiTYPER assay for quantitative DNA methylation analysis
Genomic DNAwas extracted from3× 106 PBMCs using QIAampDNA
MiniKit (Qiagen, Valencia, CA, USA). QuantitativeDNAmethylation anal-
ysis of DNMT1 and TET2 loci was performed using the EpiTYPER assay
(Sequenom, SanDiego, CA). OnemicrogramofDNAwas converted by bi-
sulﬁte using the EZ-96 DNAMethylation Kit (Zymo Research Corpora-
tion) with minor changes with respect to manufacturer's instructions.
Brieﬂy, DNA was incubated in CT buffer at 55 °C for 15 min and 95 °C
for 30 s for 21 cycles; bisulﬁte-treated DNA was eluted in 100 μl of
water. Ten nanograms of bisulﬁte-treated DNA was PCR-ampliﬁed
using the primers listed in Table 2. Three and two couples of primers
were used to cover the CpG islands of DNMT1 and of TET2 respectively.
The three DNMT1 amplicons were mapped in the following regions:
chr19: 10,305,019–10,305,247; chr19: 10,305,254–10,305,472; chr19:
10,305,451–10,305,937. The two TET2 amplicons were mapped in the
following regions: chr4: 106,067,377–106,067,737; chr4: 106,067,635–
106,068,063. Depending on the sequence context, the EpiTYPER mea-
sures the methylation status of single CpGs or groups of adjacent CpGs,
indicated as CpG units. After data cleaning, 32 CpG units (50 CpGs)
were assessed in DNMT1 CpG island, while 25 CpG units (47 CpGs)
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Correlation analysis between TET2 expression and disease duration in MS patients.
rho = −0.36; p = 0.040.
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DNAwas denatured in 0.4MNaOH, 10mMEDTAat 95 °C for 10min,
and then neutralized by adding an equal volumeof cold 2MammoniumFig. 1.A— Box-plot ofmRNA expressionmeasured by qPCR ofDNMT and TET family genes tested i
regulated inMSvs. H. Thewhiskers go down to the smallest value andup to the largest. Themedia
expressionmeasured by qPCR ofDNMT1 and TET2 tested in additional 23 H and 23MS PBMCs sam
go down to the smallest value and up to the largest. Themedian for each data set is indicated by t
DNMT1 and TET2 tested in 40H and 40MS PBMCs samples. Both gene expression levels are signiﬁ
largest. Themedian for each data set is indicated by the center line. *p≤ 0.05; **p≤ 0.01. D—Wes
(1–10) samples. Image shows a decrease in protein levels of both genes in MS vs. H samples. Anacetate (pH 7.0). Next, 2-fold dilutions of denatured DNA samples were
spotted on a nitrocellulose membrane Hybond-N+ (Amersham Biosci-
ences) in an assembled Bio-Dot apparatus (Bio-Rad). Hybond N+ is a
positively charged nylon membrane capable of high sensitivity in DNA
blotting. Vacuum was subsequently applied to ﬁlter. The blotted mem-
brane was washed with 2× SSC buffer and air-dried. The membrane
was then blocked with 5% non-fat milk and incubated with monoclonal
5meC antibody (Eurogentec) and polyclonal 5hmC antibody (Active
Motif). Binding of anHRP-conjugated secondary antibodywas visualized
by chemiluminescence (Amersham ECL Western Blotting detection re-
agents). To control equal spotting of total DNA on the membrane, the
same blot was then stained with 0.02% methylene blue in 0.3 M sodium
acetate (pH 5.2). Positive control was performed on unmethylated,
methylated and hydroxymethylated DNA standard set (Zymo Research).
3. Results
With the aim of tracing DNAmethylation changes inMS, we investi-
gated defects in DNA methylation/demethylation machinery in PBMCs
of MS patients vs. control individuals.
Attention was focused on DNMT and TET family enzymes. DNMT1,
DNMT3a and DNMT3b genes were selected and analyzed for theirn 17H and17MSPBMCs samples.DNMT1 and TET2 expression levels are signiﬁcantly down-
n for eachdata set is indicated by the center line. *p≤ 0.05; **p≤ 0.01. B—Box-plot ofmRNA
ples. Both gene expression levels are signiﬁcantly down-regulated inMS vs. H. Thewhiskers
he center line. *p≤ 0.05; **p≤ 0.01. C— Box-plot of mRNA expressionmeasured by qPCR of
cantly down-regulated inMS vs. H. Thewhiskers go down to the smallest value and up to the
tern blotting analysis of TET2 andDNMT1 performed in PBMCs from10H (1–10) and 10MS
tibody anti-LaminB1 was used as loading control.
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volved in maintenance/de novo DNA methylation [16]. TET1, TET2 and
TET3 were evaluated as they are important players in the mechanism
of active DNA demethylation [17]. Fig. 1A shows that DNMT1 and TET2
expression levels, assessed by qPCR on 17MS and H samples, are signif-
icantly down-regulated in MS vs. control individuals. This ﬁnding was
validated extending the qPCR analysis to additional PBMCs samples, fo-
cusing the attention on those geneswhose expression resulted in signif-
icant down-regulation inMS vs. control individuals. Down-regulation of
DNMT1 and TET2 in MS patients was conﬁrmed (Fig. 1B–D).
Spearman correlation analysis was performed to identify the rela-
tionship between DNMT1 and TET2 expressionswith the Expanded Dis-
ability Status Scale (EDSS) and disease duration. Interestingly, a
moderate negative correlation between TET2 and disease duration
was observed (rho =−0.36; p= 0.040) (Table 2).
As next step, we analyzed whether the down-regulation of DNMT1
and TET2 gene expression was dependent on aberrant methylation of
their promoters. Analysis of DNA methylation was carried out by the
EpiTYPER MAssARRAY, a high throughput technique which provides
quantitative estimation of methylation levels of the CpG sites within a
target region. The target regions covered the CpG island (CGI) that lo-
cates at 5′ region of both DNMT1 and TET2 genes. As shown in Fig. 2,
the methylation levels of both CGIs were very low, both for MS and H
subjects. However, some CpGs were aberrantly methylated in PBMCs
fromMS patients and, although small, the differences reached statisticalFig. 2. DNA methylation proﬁle of DNMT1 and TET2 CGIs by EpiTYPER analysis on PBMCs from
white the undetected ones. The ﬁrst exon is plotted by grey boxwhile the black box indicates th
of the CpG investigated. *p ≤ 0.05; **p ≤ 0.01.signiﬁcance for 3 CpG units in TET2 CGI. To obtain evidence of a DNA
methylome/hydroxymethylome signature, global levels of 5hmC and
5mC were assessed by dot blot with speciﬁc antibodies. Data, reported
in Fig. 3, evidenced a decrease in 5hmC level in genomic DNA of MS pa-
tients vs. healthy donors. Conversely, 5mC level appears lightly in-
creased in the genome of MS patients.
TET enzymes are also involved in inﬂammatory response through a
negative regulation of the pro-inﬂammatory cytokine IL-1β [18]. Consid-
ering the inﬂammatory component of MS, we investigated the expres-
sion of this cytokine and its correlation with TET1 and TET2 enzyme
expression. Although the increase of IL-1β observed in MS patients was
not statistically signiﬁcant (Fig. 4A), we detected an inverse correlation
between its levels and those of TET1 (rho=−0.48; p= 0.030) (Fig. 4B).
4. Discussion
Etiology of MS is little known and interest in the epigenetic events
involved in the development of this inﬂammatory disease is growing
[4]. Several environmental risk factors, such as smoking, vitamin D deﬁ-
ciency and Epstein–Barr Virus (EBV) infection, seem to predispose indi-
viduals to MS pathology [19]. Epigenetic alterations have recently been
described in MS individuals. Apart from DNA demethylated pattern
found in white brain matter of MS patients [3], H3 histone acetylation
is associated with the maintenance of the undifferentiated state of oli-
godendrocyte progenitor cells [20]. In this context, the absence of9 MS and 9 H subjects. Gray dashes show CpG dinucleotides analyzed by the instrument,
e ﬁrst intron. The white box represents CpG island of the genes. X-axis reports the number
Fig. 3.Dot blot analysis using 5hmC and 5mC speciﬁc antibodies to detect global levels of 5hmCand 5mC on two-fold dilution of genomicDNA from 4H (H1–4) and 4MS (MS 1–4) PBMCs
samples. Methylene blue staining was used as loading control. The bottom panels show speciﬁcity control dot blot analyses performed on unmethylated (C), methylated (M) and
hydroxymethylated (hM) DNA. No DNA control was performed (N).
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as it blocks the correct differentiation to mature oligodendrocytes with
drastic consequences on myelin synthesis. Epigenetic deregulation
could also affect the expression of microRNAs which are known to be
deregulated in active MS lesions and PBMCs [21].
PBMCs could represent a good substitute for brain to identify mech-
anisms as well as biomarkers in neurological disorders. Concordant
methylation changes have been shown in the brain and blood of pa-
tients affected by Parkinson disease [13]. Moreover, PBMCs seem to be
a reasonable surrogate to study the effect of age on DNA methylation
proﬁles [22]. Based on this, analysis of DNA methylation patterns was
performed on PBMCs derived from MS individuals. Our study has been
focused on the expression of the enzymes involved in DNA methyla-
tion/demethylation machinery. Deregulation of their expression could
introduce changes in DNA methylation patterns with dramatic conse-
quences in expression of genes which may determine MS risk and pro-
gression. We have found that the expression of TET2 and DNMT1, two
genes coding for enzymes which are important players in determining
DNA methylation patterns, is down-regulated in PBMCs of MS patients
both atmRNA and protein levels. This down-regulation could be asso-
ciated with signiﬁcant differences in the methylation of speciﬁc
CpGs present in their promoters. Notably, the decrease of TET2
level corresponds to the lower amount of 5hmC on the genome of
MS patients while the level of 5mC is slightly increased. The latter
could be explained by accumulation of 5mC due to the diminished
TET2 expression. However, considering the decrease of the mainte-
nance enzyme DNMT1, one would expect decreased 5mC content.
This was not detected probably because the proliferation rate of
PBMCs does not allow a detectable passive demethylation process
dependent on DNMT1 down-regulation. An alternative possibility
is that DNMT3a and b, whose levels are unchanged, exert a compen-
satory role [23,24]. Furthermore, opposite CpG methylation varia-
tions could occur at different genomic regions masking global
methylation changes in the genome.Alteration of 5-hydroxymethylation is noteworthy as 5hmC is in-
volved not only in the DNA demethylation process but also in the con-
trol of transcription. In the context of other neurodegenerative
disorders such as Alzheimer [25] and Huntington diseases [26], changes
of 5hmC levels have been reported to correlate with differences in gene
expression. This suggests a possible involvement of 5hmC in the etiolo-
gy and course of neurodegeneration processes. Notably, genome-wide
association studies identiﬁed TET2 gene among the 48 new susceptibil-
ity variants for multiple sclerosis [27]. Considering the inﬂammatory
feature of MS, the decrease of TET2 enzyme and 5hmC levels may
have consequences on inﬂammatory component of MS pathogenesis.
TET enzymes are involved in the repression of pro-inﬂammatory cyto-
kines [18] and thus down-regulation of TET proteins may favor the in-
ﬂammatory state in MS individuals.
Besides possible immunological alterations in the host, abnormali-
ties of the methylation machinery may also affect the host–microbe in-
terplay with pathogens relevant for MS etiology, an example being the
methylation state of speciﬁc CpGs in EBV DNA that control the switch
from latent to lytic infection [28].
This research highlights for the ﬁrst time aberrant DNA
hydroxymethylation in MS patients showing decrease in 5hmC levels
in PBMCs likely depending on TET2 down-regulation. The challenge
ahead will be to put these results into context, particularly as far as
they relate – functionally – to corresponding changes in the CNS. There-
fore, our data reinforce the idea that epigenetics, particularly DNA
methylation/hydroxymethylation, histone modiﬁcations and miRNA
expression [19–21], may have relevant roles in MS pathophysiology
and further research may provide new epigenetic tools for non-
invasive diagnosis and/or treatment of the disease.
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